CTLA4 and melanoma: In melanoma treatment, integrating multi-omics has enhanced the clinical efficacy of immune checkpoint inhibitors (ICIs), such as PD-1 inhibitors (nivolumab, pembrolizumab) and CTLA-4 inhibitors (ipilimumab).